RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News: Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

The release as fetched from its publisher. ractigen.com ↗